Radiation Pneumonitis - Recognition and Steroid Management

Key Points

• Radiation pneumonitis usually occurs within weeks to months after thoracic radiation.
• Diagnosis requires exclusion of infection, tumor progression, pulmonary embolism, heart failure, and other drug-related pneumonitis.
• CT abnormalities often correspond to the radiation distribution but can be less sharply bounded.
• Asymptomatic radiographic pneumonitis often needs observation rather than steroids.
• Symptomatic grade 2 or greater disease commonly requires systemic corticosteroids.
• Steroids should be tapered slowly because symptoms can recur during a rapid taper.
• Severe hypoxemia or respiratory distress requires hospitalization and broad evaluation.
• Checkpoint-inhibitor exposure changes the differential and can alter steroid dosing/management.
• Dosimetry, concurrent therapy, and underlying interstitial lung disease influence risk.
• Late radiation fibrosis is different from active pneumonitis and is less steroid responsive.

Algorithm

1. Confirm timing and retrieve the thoracic radiation dose distribution.
2. Assess cough, dyspnea, fever, oxygen saturation, exercise tolerance, and severity.
3. Obtain chest CT and compare abnormalities with the treated lung volume.
4. Exclude infection, pulmonary embolism, heart failure, tumor progression, and systemic-therapy toxicity.
5. For asymptomatic mild disease, monitor clinically and radiographically.
6. For symptomatic pneumonitis, start corticosteroid therapy after appropriate infection assessment.
7. Reassess within days to ensure symptomatic and oxygenation improvement.
8. Taper corticosteroid gradually over weeks, slowing or stepping back if symptoms recur.
9. Consider PJP prophylaxis and steroid-toxicity prevention when prolonged immunosuppression is required.
10. Manage late fibrosis with pulmonary supportive care rather than indefinite corticosteroids.

Clinical Synopsis & Reasoning

Radiation-induced lung injury has an early inflammatory phase, radiation pneumonitis, followed in some patients by later fibrosis. Symptoms usually emerge within several weeks to six months after thoracic radiation, though timing varies with dose, fractionation, combined systemic therapy, and individual susceptibility. Typical symptoms are dry cough, exertional dyspnea, low-grade fever, chest discomfort, and reduced exercise tolerance. Hypoxemia and respiratory failure can occur in severe cases.

The diagnosis is clinical and radiographic because there is no single confirmatory blood test. CT often shows ground-glass opacity or consolidation that conforms partly to the irradiated lung volume, although changes can extend beyond sharp field boundaries. Later fibrosis produces volume loss, traction bronchiectasis, and architectural distortion. Comparing CT abnormalities with the radiation treatment plan is highly informative and should be part of specialist review.

The differential diagnosis is broad and clinically important. Infection is common in patients with cancer and can coexist with radiation injury. Immune checkpoint inhibitor pneumonitis, chemotherapy toxicity, opportunistic infection, pulmonary embolism, lymphangitic tumor spread, recurrent cancer, COPD exacerbation, and heart failure can present similarly. Fever, neutropenia, sputum, biomarker patterns, cultures, viral testing, CT distribution, and response to therapy help refine the diagnosis. Bronchoscopy is not required for every case but is useful when infection, hemorrhage, or tumor progression remains uncertain, particularly in immunocompromised or severely ill patients.

Risk is influenced by dosimetry and host factors. Higher mean lung dose, larger volume receiving intermediate or high dose, concurrent chemoradiation, preexisting interstitial lung disease, some targeted therapies, and immune checkpoint inhibitors can increase risk. Smoking history has complex associations and should not be considered protective. Modern conformal planning reduces normal-lung exposure, but clinically important pneumonitis still occurs after conventional chemoradiation and selected SBRT scenarios.

Severity grading should reflect symptoms and oxygen requirement rather than CT appearance alone. Radiographic changes without symptoms can be observed. Limiting exertional dyspnea that requires medical intervention is generally treated. New oxygen requirement, resting dyspnea, or respiratory distress warrants urgent evaluation, hospitalization, and exclusion of infection or other life-threatening causes.

Treatment Strategy & Disposition

For symptomatic radiation pneumonitis, corticosteroids are the mainstay after reasonable exclusion of infection. Contemporary European guidance supports approximately prednisone 0.5 mg/kg/day for grade 2 pneumonitis in patients who have not received immunotherapy, with regimen adjusted to severity and context. Other commonly used regimens begin around 20 to 40 mg daily for moderate disease. More severe pneumonitis may require higher-dose oral prednisone or IV methylprednisolone. There is no single universal regimen, so the dose should be individualized by severity and whether checkpoint-inhibitor pneumonitis is also possible.

Steroids should be continued long enough to achieve improvement and then tapered gradually, often over at least several weeks. Relapse during taper is common if therapy is reduced too quickly. Return to the previously effective dose and a slower taper may be needed. Patients receiving prolonged moderate-to-high-dose corticosteroids require monitoring for hyperglycemia, hypertension, mood changes, myopathy, osteoporosis, gastritis, and infection. Pneumocystis prophylaxis should be considered when steroid dose and duration cross institutionally accepted immunosuppression thresholds.

Supportive care includes oxygen for hypoxemia, bronchodilators when obstructive airway disease contributes, pulmonary rehabilitation in recovery, and vaccination/infection prevention. Antibiotics are not a treatment for sterile radiation injury but may be appropriate while infection is being evaluated in an unstable or immunocompromised patient. Severe respiratory failure requires inpatient management, often with pulmonary and infectious-disease consultation.

Radiation fibrosis is not generally reversed by corticosteroids once the active inflammatory phase has passed. Long-term management focuses on oxygen when indicated, pulmonary rehabilitation, treatment of comorbid lung disease, and symptom management. Persistent or atypical imaging should be reviewed for recurrence because post-radiation change can evolve for months to years.

Epidemiology / Risk Factors

• Clinically significant pneumonitis occurs in a minority of patients receiving thoracic radiotherapy, with risk varying widely by disease and regimen.
• Concurrent chemoradiation for lung cancer carries greater risk than many small-field palliative courses.
• Underlying interstitial lung disease markedly increases risk of severe radiation lung injury.
• Use of immunotherapy before or after thoracic radiation has increased diagnostic overlap with immune-mediated pneumonitis.
• Modern dose-volume constraints reduce but do not eliminate risk.

Investigations

Risk Factors

Pharmacology

Prognosis / Complications

• Most mild to moderate cases improve with corticosteroids and time.
• Severe pneumonitis can progress to respiratory failure and can be fatal.
• Some patients develop persistent fibrosis and chronic exercise limitation despite resolution of inflammation.
• Recurrence during steroid taper is common enough to justify gradual reduction and close monitoring.
• Underlying lung function, treated lung volume, and concurrent systemic therapy influence recovery.

Patient Education / Counseling

• Tell patients receiving chest radiation to report new dry cough, shortness of breath, fever, or reduced exercise capacity even if symptoms begin months after treatment.
• Explain that radiation pneumonitis is inflammation rather than an infection, but infection must often be excluded before treatment.
• Review steroid adverse effects and the importance of following the taper exactly.
• Advise urgent evaluation for severe breathlessness at rest, blue discoloration, confusion, chest pain, hemoptysis, or rapidly increasing oxygen needs.
• Encourage smoking cessation, vaccination, pulmonary rehabilitation, and treatment of underlying COPD or asthma when applicable.

Notes

A 2025 ESTRO guideline provides a structured approach to diagnosis and treatment of radiation-induced pneumonitis and supports corticosteroid therapy for symptomatic disease, with dose tailored to grade and prior immunotherapy exposure. This is preferable to rigidly applying one prednisone dose to every patient.

Radiation pneumonitis is often a diagnosis of probability. The strongest case combines compatible timing, symptoms, CT pattern, treatment-plan overlap, and a negative evaluation for competing diagnoses. If any component is atypical, the threshold for pulmonary, infectious-disease, or oncology review should be lower.

Long steroid courses create their own morbidity. Bone protection, glucose monitoring, infection prophylaxis, gastric protection when indicated, and a documented taper plan are part of treatment, not optional afterthoughts.

References

1. ESTRO Guideline on Diagnosis and Treatment of Radiation Induced Pneumonitis 2025 — Link
2. ASTRO Thoracic Radiation Oncology Resources — Link